News & Updates
Filter by Specialty:

Is liposomal irinotecan superior to topotecan in relapsed small cell lung cancer?
Treatment with liposomal irinotecan in adults with relapsed small cell lung cancer (SCLC) achieves similar overall survival (OS) when compared with topotecan, but the former is associated with a higher overall response rate (ORR), according to the results of RESILIENT, randomized, open-label phase III trial.
Is liposomal irinotecan superior to topotecan in relapsed small cell lung cancer?
07 Jun 2023
T2DM: SGLT2 inhibitors associated with lower rates of ICU admission and all-cause mortality
A retrospective observational study of nearly 28,000 patients with type 2 diabetes mellitus (T2DM) in Hong Kong finds that use of sodium-glucose cotransporter 2 (SGLT2) inhibitors is independently associated with lower rates of ICU admission and all-cause mortality across various disease categories.
T2DM: SGLT2 inhibitors associated with lower rates of ICU admission and all-cause mortality
07 Jun 2023
Does extended lymph node sampling increase complications?
Patients undergoing more extensive lymph node sampling during surgery for a suspected malignant paediatric renal tumour do not appear to have a higher likelihood of experiencing clinically significant complications, reveals a study.
Does extended lymph node sampling increase complications?
06 Jun 2023
Nivolumab-chemo poised to alter NSCLC treatment landscape
In the 3-year analysis of the phase III CheckMate 816 trial, neoadjuvant nivolumab plus platinum doublet chemotherapy (nivo-chemo) continued to provide durable benefit for individuals with resectable non-small-cell lung cancer (NSCLC).